+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

P-4-47 Effects of clozapine on plasma monoamine metabolites in treatment-refractory schizophrenic patients



P-4-47 Effects of clozapine on plasma monoamine metabolites in treatment-refractory schizophrenic patients



European Neuropsychopharmacology 5(3): 341-342




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 062474359

Download citation: RISBibTeXText

DOI: 10.1016/0924-977x(95)90567-w


Related references

Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Therapeutic Drug Monitoring 18(2): 200-207, 1996

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. American Journal of Psychiatry 152(2): 179-182, 1995

Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30(2): 251-264, 2005

Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. American Journal of Psychiatry 148(2): 231-235, 1991

Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Therapeutic Drug Monitoring 21(3): 341-345, 1999

Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. Journal of Clinical Psychiatry 59(10): 521-527, 1998

Effects of venlafaxine treatment on clozapine plasma levels in schizophrenic patients. Neuropsychobiology 51(4): 173-176, 2005

Clozapine and metabolites plasma levels in resistant schizophrenic patients. Journal de Pharmacie Clinique 18(3): 244-250, 1999

Gender differences in plasma clozapine levels and its metabolites in schizophrenic patients. Human Psychopharmacology. 12(5): 489-495,.-., 1997

Should chronic treatment refractory akathisia be an indication for the use of clozapine in schizophrenic patients?. Journal of Clinical Psychiatry 53(7): 248-251, 1992

Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. Journal of Pharmaceutical & Biomedical Analysis 26(2): 301-311, 2001

Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochemistry International 56(6-7): 774-779, 2010

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry. 34(10): 702-712, 1993

Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. British Journal of Psychiatry 147: 276-282, 1985

Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia 40(4): 341-350, 1975